hVIVO Appoints Tracey James as Independent Non-Executive Director

Open Orphan Plc ( (GB:HVO) ) has provided an update.

hVIVO plc has appointed Tracey James as an Independent Non-Executive Director, effective from June 1, 2025. With extensive experience in audit and risk management, particularly with AIM-listed companies, Tracey is expected to strengthen the board’s expertise as hVIVO continues to integrate its diverse revenue streams and deliver progress for clients and shareholders.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £35.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.

The stock is supported by strong financial performance and strategic corporate actions that enhance growth prospects. While technical indicators show moderate momentum, valuation metrics are favorable. Positive corporate events further bolster the stock’s outlook, although governance concerns are noted.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials, offering end-to-end clinical development services to a diverse client base, including major biopharma companies. The company specializes in human challenge trials for infectious and respiratory diseases, operates a state-of-the-art quarantine facility in London, and provides comprehensive virology and immunology laboratory services. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and drug development consulting, ensuring a seamless pathway from discovery to late-stage development.

Average Trading Volume: 1,499,423

Technical Sentiment Signal: Sell

Current Market Cap: £109.9M

For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.